

Actinogen Medical attending BIO 2017

- Actinogen Medical presenting at BIO International Convention, the world's largest and most prestigious biotechnology convention in San Diego, this month.
- BIO International attracts the global biotech industry to network on new opportunities and partnerships.
- Ideal forum to showcase Actinogen Medical and Xanamem, including the successful initiation of our XanADu Alzheimer's Disease trial and plans to initiate a second Phase II trial of Xanamem in Diabetes Cognitive Impairment.

Sydney 19 June 2017. Actinogen Medical (ASX: ACW) is pleased to announce that the Company's CEO, Dr. Bill Ketelbey, is leading the Actinogen team and presenting at the BIO International Convention in San Diego in June 2017. This follows the successful initiation of XanADu, its Phase II trial of Xanamem in Alzheimer's Disease, and the progress made towards the commencement of a second Phase II trial of Xanamem in Diabetes Cognitive Impairment.

The BIO International Convention, hosted by the Biotechnology Innovation Organisation (BIO), is the largest global convention for the biotechnology industry and attracts the biggest and best organisations in biotech to network on new opportunities and potential partnerships. Participation at BIO offers Actinogen Medical unparalleled networking opportunities to showcase Xanamem and the quality research that supports its development.

The BIO presentation is attached.

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's Disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's Disease is estimated to be US\$250bn, and is set to increase to US\$2 trillion by 2050, outstripping the treatment costs of all other diseases. Alzheimer's Disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia.

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11 β -HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's Disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's Disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem, in subjects with mild dementia due to Alzheimer's Disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699.